The Coalition comprises many of the world’s most innovative diagnostic technology companies, clinical laboratories, physicians, venture capital companies, and patient advocacy groups.
Given the Coalition’s mission to facilitate development and commercialization of innovative diagnostics to inform important patient management decisions, we have a keen interest in the agency’s CLFS payment policies and determinations – especially those addressing coding and payment for: (1) Multianalyte Assays with Algorithmic Analyses (MAAA) and (2) Genomic Sequencing Procedures and other Molecular Multianalyte Assays.
Will earlier ordering improve test result quality and delivery?
Working with viable specimens, producing better results, and providing faster turnaround times?
We continue to support the implementation of PAMA on the schedule set out in the CLFS Final Rule, which sets an effective date of January 1, 2018 for the new market-based payment rates.
Additionally, we respectfully request that CMS release the application for Advanced Diagnostic Laboratory Test (ADLT) status as soon as practicable to enable qualifying tests to be designated in advance of CY 2018.
Additionally, the Coalition has been actively engaged with other critical stakeholders such as the American Medical Association CPT Editorial Panel on coding policy, and with the Medicare Administrative Contractors (MAC) on coverage policy and evidentiary requirements.